GlassScriptPhysician profile
Wen Xiong
NPI 1447408216
$48,884.63
in general payments reported to CMS, 2019-2025
51 companies · $6,530 in 2025
The $6,530 reported for 2025 was more than what 88% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,434 · 2020: $1,475 · 2021: $6,069 · 2022: $11K · 2023: $15K · 2024: $6,732 · 2025: $6,530.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Food and Beverage: $8,481 · Consulting Fee: $6,000 · Travel and Lodging: $2,358 · Education: $390.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,800.00 |
| Food and Beverage | $8,481.19 |
| Consulting Fee | $6,000.00 |
| Travel and Lodging | $2,357.73 |
| Education | $389.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $33,727.07 | 2019-2025 | Ofev, Jascayd, Cyltezo |
| Abbvie INC. | $2,413.60 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Janssen Biotech, INC. | $1,936.58 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Amgen INC. | $1,538.28 | 2019-2025 | Tavneos, Enbrel, Otezla |
| Pfizer INC. | $1,341.26 | 2019-2025 | |
| Ucb, INC. | $1,021.54 | 2019-2025 | Cimzia, Bimzelx |
| Novartis Pharmaceuticals Corporation | $868.57 | 2019-2025 | |
| Ani Pharmaceuticals, INC. | $778.49 | 2022-2025 | Purified Cortrophin Gel |
| E.R. Squibb & Sons, L.L.C. | $624.56 | 2019-2025 | Orencia |
| Glaxosmithkline, LLC. | $560.20 | 2019-2025 | Benlysta, Nucala |
| Novo Nordisk INC | $410.62 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $408.77 | 2022-2025 | Saphnelo |
| Mallinckrodt Hospital Products INC. | $343.47 | 2020-2025 | Acthar |
| Horizon Therapeutics Plc | $339.99 | 2019-2023 | Krystexxa |
| Genzyme Corporation | $329.75 | 2019-2025 |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $288.07 | 2023-2025 | Idacio, Sodium Chloride |
| Genentech USA, INC. | $211.08 | 2019-2025 | Actemra |
| Alexion Pharmaceuticals, INC. | $172.68 | 2021-2025 | Strensiq, Ultomiris |
| Celgene Corporation | $126.79 | 2019 | |
| Dexcom, INC. | $124.25 | 2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161) |
| Intra-Sana Laboratories | $111.11 | 2024 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Organon LLC | $109.88 | 2021-2025 | Hadlima, Renflexis |
| Arbor Pharmaceuticals, INC. | $95.53 | 2019-2021 | |
| Janssen Scientific Affairs, LLC | $90.60 | 2024 | Tremfya |
| Sobi, INC | $85.03 | 2020-2025 | |
| Aurinia Pharma U.S., INC. | $74.88 | 2021-2025 | Lupkynis |
| Hikma Pharmaceuticals USA | $66.11 | 2019-2022 | |
| Sandoz INC. | $61.22 | 2023-2024 | Hyrimoz |
| Sanofi-Aventis U.S. LLC | $55.00 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $47.62 | 2024 | Arcalyst |
| Lilly USA, LLC | $47.23 | 2019-2022 | |
| Azurity Pharmaceuticals, INC. | $46.23 | 2023-2024 | Horizant, Horizant |
| Kiniksa Pharmaceuticals, LTD. | $42.55 | 2023 | Arcalyst |
| Genentech, INC. | $39.95 | 2019 | |
| Mallinckrodt Enterprises LLC | $38.50 | 2019 | |
| Depuy Synthes Sales INC. | $37.59 | 2020-2024 | Orthovisc |
| Argenx US, INC. | $33.28 | 2025 | Vyvgart Hytrulo |
| United Therapeutics Corporation | $29.53 | 2023-2024 | Tyvaso |
| Bioventus LLC | $26.67 | 2022 | |
| Merck Sharp & Dohme LLC | $26.36 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $19.06 | 2019 | |
| Kyowa Kirin, INC. | $17.01 | 2024 | Crysvita |
| Scilex Pharmaceuticals INC. | $15.24 | 2024 | |
| Daiichi Sankyo INC. | $14.15 | 2019 | |
| Pacira Therapeutics, INC. | $14.00 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.82 | 2019 | |
| Antares Pharma, INC. | $12.95 | 2019 | |
| Zyla Life Sciences, INC. | $12.91 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $12.00 | 2022 | |
| Avion Pharmaceuticals | $11.96 | 2020 | |
| Medexus Pharma, INC. | $11.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wen Xiong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.